Flavonoids Inhibit COX-1 and COX-2 Enzymes and Cytokine/Chemokine Production in Human Whole Blood

Inflammation

Volumn 38, Issue 2, 2015, Pages 858-870

  Ribeiro, Daniela ^a   Freitas, Marisa ^a   Tomé, Sara M ^b   Silva, Artur M S ^b   Laufer, Stefan ^c   Lima, José L F C ^a   Fernandes, Eduarda ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

chemokine; COX; cytokines; flavonoids; human whole blood assay

Indexed keywords

CHEMOKINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FLAVONOID; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; HUMAN;

CHEMOKINES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; FLAVONOIDS; HUMANS;

EID: 84939895701     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9995-x     Document Type: Article

References (54)

1. Feghali C.A., Wright T.M. 1997. Cytokines in acute and chronic inflammation. Frontiers in Bioscience 2d12-26.
2. Dubois, R.N., S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, et al. 1998. Cyclooxygenase in biology and disease. FASEB Journal 12(12): 1063–1073.
3. Brooks, P., P. Emery, J.F. Evans, H. Fenner, C.J. Hawkey, et al. 1999. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 38(8): 779–788.
4. Cerella, C., C. Sobolewski, M. Dicato, and M. Diederich. 2010. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochemical Pharmacology 80(12): 1801–1815.
5. Mino, T., E. Sugiyama, H. Taki, A. Kuroda, N. Yamashita, et al. 1998. Interleukin-1 alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E-2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts. Arthritis and Rheumatism 41(11): 2004–2013.
6. Kushner, I. 1998. Semantics, inflammation, cytokines and common sense. Cytokine & Growth Factor Reviews 9(3–4): 191–196.
7. Charo, I.F., and R.M. Ransohoff. 2006. Mechanisms of disease—the many roles of chemokines and chemokine receptors in inflammation. New England Journal of Medicine 354(6): 610–621.
8. Adams, D.H., and A.R. Lloyd. 1997. Chemokines: leucocyte recruitment and activation cytokines. Lancet 349(9050): 490–495.
9. Gottlieb, S. 2001. COX 2 inhibitors may increase risk of heart attack. British Medical Journal 323(7311): 471–471.
10. Funk, C.D., and G.A. FitzGerald. 2007. COX-2 inhibitors and cardiovascular risk. Journal of Cardiovascular Pharmacology 50(5): 470–479.
11. Rouzer, C.A., and L.J. Marnett. 2009. Cyclooxygenases: structural and functional insights. Journal of Lipid Research 50: S29–S34.
12. Fantuzzi, G., and P. Ghezzi. 1993. Glucocorticoids as cytokine inhibitors—role in neuroendocrine control and therapy of inflammatory diseases. Mediators of Inflammation 2(4): 263–270.
13. Prud’homme, G.J. 2000. Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors. Journal of Gene Medicine 2(4): 222–232.
14. Firestein, G.S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423(6937): 356–361.
15. Falcone Ferreyra, M.L., S.P. Rius, and P. Casati. 2012. Flavonoids: biosynthesis, biological functions, and biotechnological applications. Frontiers in plant science 3: 222.
16. Brunetti, C., M. Di Ferdinando, A. Fini, S. Pollastri, and M. Tattini. 2013. Flavonoids as antioxidants and developmental regulators: relative significance in plants and humans. International Journal of Molecular Sciences 14(2): 3540–3555.
17. Gomes, A., E. Fernandes, J.L.F.C. Lima, L. Mira, and M.L. Corvo. 2008. Molecular mechanisms of anti-inflammatory activity mediated by flavonoids. Current Medicinal Chemistry 15(16): 1586–1605.
18. Gomes, A., D. Couto, A. Alves, I. Dias, M. Freitas, et al. 2012. Trihydroxyflavones with antioxidant and anti-inflammatory efficacy. Biofactors 38(5): 378–386.
19. Ribeiro, D., M. Freitas, S.M. Tomé, A.M.S. Silva, G. Porto, et al. 2013. Modulation of human neutrophils’ oxidative burst by flavonoids. European Journal of Medicinal Chemistry 67: 280–292.
20. Ribeiro, D., M. Freitas, S.M. Tome, A.M. Silva, G. Porto, et al. 2014. Inhibition of LOX by flavonoids: a structure-activity relationship study. European Journal of Medicinal Chemistry 72: 137–145.
21. Laufer S., Luik S. 2010. Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors. In: Ayoub SS, editor. Cyclooxygenases: Methods and Protocols. Vol. 644. Philadelphia: Springer Science+Business Media, LLC, 91–116.
22. Laufer, S., C. Greim, S. Luik, S.S. Ayoub, and F. Dehner. 2008. Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity. Inflammopharmacology 16(4): 155–161.
23. Myrianthefs, P., S. Karatzas, K. Venetsanou, E. Grouzi, P. Evagelopoulou, et al. 2003. Seasonal variation in whole blood cytokine production after LPS stimulation in normal individuals. Cytokine 24(6): 286–292.
24. Windheim, M., C. Lang, M. Peggie, L.A. Plater, and P. Cohen. 2007. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochemical Journal 404(2): 179–190.
25. Luong, C., A. Miller, J. Barnett, J. Chow, C. Ramesha, et al. 1996. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Structural Biology 3(11): 927–933.
26. Kurumbail, R.G., A.M. Stevens, J.K. Gierse, J.J. McDonald, R.A. Stegeman, et al. 1996. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384(6610): 644–648.
27. Wang, H., M.G. Nair, G.M. Strasburg, A.M. Booren, I. Gray, et al. 2000. Cyclooxygenase active bioflavonoids from Balaton™ tart cherry and their structure activity relationships. Phytomedicine 7(1): 15–19.
28. Llorens, O., J.J. Perez, A. Palomer, and D. Mauleon. 2002. Differential binding mode of diverse cyclooxygenase inhibitors. Journal of Molecular Graphics & Modelling 20(5): 359–371.
29. D’Mello, P., M.K. Gadhwal, U. Joshi, and P. Shetgiri. 2011. Modeling of cox-2 inhibotory activity of flavonoids. International Journal of Pharmacy and Pharmaceutical Sciences 3(4): 33–40.
30. Hou, D.X., T. Yanagita, T. Uto, S. Masuzaki, and M. Fujii. 2005. Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: structure-activity relationship and molecular mechanisms involved. Biochemical Pharmacology 70(3): 417–425.
31. Feng, L., Y. Xia, G.E. Garcia, D. Hwang, and C.B. Wilson. 1995. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. Journal of Clinical Investigation 95(4): 1669–1675.
32. Landino, L.M., B.C. Crews, M.D. Timmons, J.D. Morrow, and L.J. Marnett. 1996. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proceedings of the National Academy of Sciences of the United States of America 93(26): 15069–15074.
33. Baumann, J., F. von Bruchhausen, and G. Wurm. 1980. Flavonoids and related compounds as inhibition of arachidonic acid peroxidation. Prostaglandins 20(4): 627–639.
34. Landolfi, R., R.L. Mower, and M. Steiner. 1984. Modification of platelet-function and arachidonic-acid metabolism by bioflavonoids—structure activity relations. Biochemical Pharmacology 33(9): 1525–1530.
35. Kim, H.P., K.H. Son, H.W. Chang, and S.S. Kang. 2004. Anti-inflammatory plant flavonoids and cellular action mechanisms. Journal of Pharmaceutical Sciences 96(3): 229–245.
36. Lopez-Posadas, R., I. Ballester, C. Mascaraque, M.D. Suarez, A. Zarzuelo, et al. 2010. Flavonoids exert distinct modulatory actions on cyclooxygenase 2 and NF-kappaB in an intestinal epithelial cell line (IEC18). British Journal of Pharmacology 160(7): 1714–1726.
37. Liang, Y.C., Y.T. Huang, S.H. Tsai, S.Y. Lin-Shiau, C.F. Chen, et al. 1999. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20(10): 1945–1952.
38. Raso, G.M., R. Meli, G. Di Carlo, M. Pacilio, and R. Di Carlo. 2001. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life sciences 68(8): 921–931.
39. Vitale, P., S. Tacconelli, M.G. Perrone, P. Malerba, L. Simone, et al. 2013. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. Journal of Medicinal Chemistry 56(11): 4277–4299.
40. Fiorucci, S., R. Meli, M. Bucci, and G. Cirino. 2001. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochemical Pharmacology 62(11): 1433–1438.
41. Martel-Pelletier, J., D. Lajeunesse, P. Reboul, and J.P. Pelletier. 2003. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Annals of the Rheumatic Diseases 62(6): 501–509.
42. Wright, H.L., R.J. Moots, R.C. Bucknall, and S.W. Edwards. 2010. Neutrophil function in inflammation and inflammatory diseases. Rheumatology 49(9): 1618–1631.
43. Santangelo, C., R. Vari, B. Scazzocchio, R. Di Benedetto, C. Filesi, et al. 2007. Polyphenols, intracellular signalling and inflammation. Annali dell Istituto superiore di sanita 43(4): 394–405.
44. Burger, D., J.M. Dayer, G. Palmer, and C. Gabay. 2006. Is IL-I a good therapeutic target in the treatment of arthritis? Best Practice & Research in Clinical Rheumatology 20(5): 879–896.
45. Kim, E.Y., and K.D. Moudgil. 2008. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunology Letters 120(1–2): 1–5.
46. Proost, P., C. Dewolfpeeters, R. Conings, G. Opdenakker, A. Billiau, et al. 1993. Identification of a novel granulocyte chemotactic protein (Gcp-2) from human tumor-cells - in vitro and in vivo comparison with natural forms of Grp, Ip-10, and Il-8. Journal of Immunology 150(3): 1000–1010.
47. Proost, P., A. Wuyts, and J. VanDamme. 1996. The role of chemokines in inflammation. International Journal of Clinical & Laboratory Research 26(4): 211–223.
48. Schnyder-Candrian, S., R.M. Strieter, S.L. Kunkel, and A. Walz. 1995. Interferon-alpha and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes. Journal of Leukocyte Biology 57(6): 929–935.
49. Comalada, M., I. Ballester, E. Bailon, S. Sierra, J. Xaus, et al. 2006. Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochemical Pharmacology 72(8): 1010–1021.
50. Calixto, J.B., M.M. Campos, M.F. Otuki, and A.R.S. Santos. 2004. Anti-inflammatory compounds of plant origin. Part II. Modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Medica 70(2): 93–103.
51. Min, Y.D., C.H. Choi, H. Bark, H.Y. Son, H.H. Park, et al. 2007. Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappa B and p38 MAPK in HMC-1 human mast cell line. Inflammation Research 56(5): 210–215.
52. Xagorari, A., A. Papapetropoulos, A. Mauromatis, M. Economou, T. Fotsis, et al. 2001. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. Journal of Pharmacology and Experimental Therapeutics 296(1): 181–187.
53. Ueda, H., C. Yamazaki, and M. Yamazaki. 2002. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biological & Pharmaceutical Bulletin 25(9): 1197–1202.
54. Kotanidou, A., A. Xagorari, E. Bagli, P. Kitsanta, T. Fotsis, et al. 2002. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. American Journal of Respiratory and Critical Care Medicine 165(6): 818–823.